Eapen A, Kloepfer KM (2018) Serum sickness-like reaction in a pediatric patient using omalizumab for chronic spontaneous urticaria. Pediatric Allergy Immunology 29:449–450
Afrin LB, Butterfield JH, Raithel M, Molderings GJ (2016) Often seen, rarely recognized: mast cell activation disease - a guide to diagnosis and therapeutic options. Ann Med 48:190–201
CAS
PubMed
Google Scholar
Afrin LB, Self S, Menk J, Lazarchick J (2017) Characterization of mast cell activation syndrome. Am J Med Sci 353:207–215
PubMed
Google Scholar
Akin C (2014) Mast cell activation disorders. J Allergy Clin Immunol: In Practice 2:252–257
Google Scholar
Althin M (2018) Evaluation of Xolair® (omalizumab) therapy in patients treated at Örebro University Hospital 2006-2017. Örebro University Hospital, Örebro, Sweden, Medical Thesis
Belliveau PP (2005) Omalizumab: a monoclonal anti-IgE antibody. Med Gen Med 7:27
Google Scholar
Berger W, Gupta N, McAlary M, Fowler-Taylor A (2003) Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Annals of Allergy, Asthma & Immunology 91:182–188
Bölke G, Church MK, Bergmann KC (2019) Comparison of extended intervals and dose reduction of omalizumab for asthma control. Allergo J Int 28:1–4
Google Scholar
Broesby-Olsen S, Vestergaard H, Mortz CG, Jensen B, Havelund T, Hermann AP, Siebenhaar F, Møller MB, Kristensen TK, Bindslev-Jensen C, Mastocytosis Centre Odense University Hospital (MastOUH) (2018) Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations. Allergy 73:230–238
CAS
PubMed
Google Scholar
Cardamone C, Parente R, Feo GD, Triggiani M (2016) Mast cells as effector cells of innate immunity and regulators of adaptive immunity. Immunol Lett 178:10–14
CAS
PubMed
Google Scholar
Chang TW (2000) The pharmacological basis of anti-IgE therapy. Nat Biotechnol 18:157–162
CAS
PubMed
Google Scholar
Chipps BE, Zeiger RS, Luskin AT, Busse WW, Trzaskoma BL, Antonova EN, Pazwash H, Limb SL, Solari PG, Griffin NM, Casale TB (2017) Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. Ann Allergy Asthma Immunol 119:524–532
Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P (2009) Safety and tolerability of omalizumab. Clin Exp Allergy 39:788–797
Davies AM, Allan EG, Keeble AH, Delgado J, Cossins BP, Mitropoulou AN, Pang MOY, Ceska T, Beavil AJ, Craggs G, Westwood M, Henry AJ, McDonnell JM, Sutton BJ (2017) Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab. J Biol Chem 292:9975–9987
CAS
PubMed
PubMed Central
Google Scholar
Dreyfus DH, Randolph CC (2006) Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol 96:624–627
PubMed
Google Scholar
Foroughi S, Foster B, Kim N, Bernardino LB, Scott LM, Hamilton RG, Metcalfe DD, Mannon PJ, Prussin C (2007) Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 120:594–601
CAS
PubMed
PubMed Central
Google Scholar
Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES (1996) Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26:690–696
CAS
PubMed
Google Scholar
Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J (2007) Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol 144:155–158
PubMed
Google Scholar
Harrison RG, MacRae M, Karsh J, Santucci S, Yang WH (2015) Anaphylaxis and serum sickness in patients receiving omalizumab: reviewing the data in light of clinical experience. Annals of Allergy, Asthma & Immunology 115:77–78
Ibelgaufts H (2019) Mast cells. Cytokines Online Pathfinder Encyclopedia. http://www.cells-talk.com/index.php/page/copelibrary?key=mast%20cells, accessed October 9, 2019
Incorvaia C, Mauro M, Russello M, Formigoni C, Riario-Sforza GG, Ridolo E (2014) Omalizumab, an anti-immunoglobulin E antibody: state of the art. Drug Des Devel Ther 8:197–207
CAS
PubMed
PubMed Central
Google Scholar
Jachiet M, Samson M, Cottin V, Kahn JE, Le Guenno G, Bonniaud P, Devilliers H, Bouillet L, Gondouin A, Makhlouf F, Meaux-Ruault N, Gil H, Bienvenu B, Coste A, Groh M, Giraud V, Dominique S, Godeau B, Puéchal X, Khouatra C, Ruivard M, Le Jeunne C, Mouthon L, Guillevin L, Terrier B, French Vasculitis Study Group (2016) Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheumatol 68:2274–2282
CAS
PubMed
Google Scholar
Jandus P, Hausmann O, Haeberli G, Gentinetta T, Mueller U, Helbling A (2011) Unpredicted adverse reaction to omalizumab. J Investig Allergol Clin Immunol 21:563–566
Kavati A, Zhdanava M, Ortiz B, LeCocq J, Schiffman B, Pilon D, Ching Cheung H, Lefebvre P, Stone BD (2019) Long-term omalizumab outcomes in chronic idiopathic urticaria: a real-world study. Allergy Asthma Proc 40:321–328
CAS
PubMed
Google Scholar
Klyucheva M, von Berg A, Gappa M, Suerbaum C, Berdel D (2013) Omalizumab therapy in adolescents with severe allergic asthma - results of a post-marketing surveillance. Pneumologie 67:233–237
Kumar SS (2019) Possible omalizumab-induced arthritis. Rheumatology Consultant [published online May 20, 2019]
Lazaridis N, Germanidis G (2018) Current insights into the innate immune system dysfunction in irritable bowel syndrome. Ann Gastroenterol 31:171–187
PubMed
PubMed Central
Google Scholar
Lemal R, Fouquet G, Terriou L, Vaes M, Livideanu CB, Frenzel L, Barete S, Canioni D, Lhermitte L, Rossignol J, Arock M, Dubreuil P, Lortholary O, Hermine O (2019) Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS. J Allergy Clin Immunol Pract 7:2387–2395
PubMed
Google Scholar
Lowe PJ, Tannenbaum S, Gautier A, Jimenez P (2009) Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 68:61–76
CAS
PubMed
PubMed Central
Google Scholar
Lyons JJ, Yu X, Hughes JD, Le QT, Jamil A, Bai Y, Ho N, Zhao M, Liu Y, O’Connell MP, Trivedi NN, Nelson C, DiMaggio T, Jones N, Matthews H, Lewis KL, Oler AJ, Carlson RJ, Arkwright PD, Hong C, Agama S, Wilson TM, Tucker S, Zhang Y, McElwee JJ, Pao M, Glover SC, Rothenberg ME, Hohman RJ, Stone KD, Caughey GH, Heller T, Metcalfe DD, Biesecker LG, Schwartz LB, Milner JD (2016) Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 48:1564–1569
CAS
PubMed
PubMed Central
Google Scholar
Mariani G, Strober W (1990) Immunoglobulin metabolism. In: Metzger H. Washington DC (eds) American Society of Microbiology Receptors and the Action of Antibodies. pp94–177
Marshall JS, King CA, McCurdy JD (2003) Mast cell cytokine and chemokine responses to bacterial and viral infection. Curr Pharm Des 9:11–24
CAS
PubMed
Google Scholar
Molderings GJ, Raithel M, Kratz F, Azemar M, Haenisch B, Harzer S, Homann J (2011) Omalizumab treatment of systemic mast cell activation disease: experiences from four cases. Intern Med 50:611–615
CAS
PubMed
Google Scholar
Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, Nöthen MM (2013) Familial occurrence of systemic mast cell activation disease. PLoS One 8:e76241
CAS
PubMed
PubMed Central
Google Scholar
Molderings GJ, Haenisch B, Brettner S, Homann J, Menzen M, Dumoulin FL, Panse J, Butterfield J, Afrin LB (2016) Pharmacological treatment options for mast cell activation disease. Naunyn Schmiedeberg’s Arch Pharmacol 389:671–694
CAS
Google Scholar
Molimard M, Mala L, Bourdeix I, Le Gros V (2014) Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control. Respir Med 108:571–576
CAS
PubMed
Google Scholar
Nopp A, Johansson SG, Ankerst J, Palmqvist M, Oman H (2007) CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment. Allergy 62:1175–1181
CAS
PubMed
Google Scholar
Nopp A, Johansson SG, Adédoyin J, Ankerst J, Palmqvist M, Oman H (2010) After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 65:56–60
CAS
PubMed
Google Scholar
Pabst S, Tiyerili V, Grohe C (2008) Apparent response to anti-IgE therapy in two patients with refractory “forme fruste” of Churg-Strauss syndrome. Thorax 63:747–748
CAS
PubMed
Google Scholar
Pavlicek V (2014) Glukokortikoide richtig ausschleichen: warum, wann und wie? Schweiz Med Forum 14:398–401
Google Scholar
Pennington LF, Tarchevskaya S, Brigger D, Sathiyamoorthy K, Graham MT, Nadeau KC, Eggel A, Jardetzky TS (2016) Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nat Commun 19:11610–11621
Google Scholar
Peterson MR, Coop CA (2017) Long-term omalizumab use in the treatment of exercise-induced anaphylaxis. Allergy Rhinol (Providence) 8:170–172
Google Scholar
Pilette C, Coppens N, Houssiau FA, Rodenstein DO (2007) Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol 120:972–973
PubMed
Google Scholar
Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM (1993) Humanization of an antibody directed against IgE. J Immunol 151:2623–2632
CAS
PubMed
Google Scholar
Presta L, Shields R, O’Connell L, Lahr S, Porter J, Gorman C, Jardieu P (1994) The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 269:26368–26373
CAS
PubMed
Google Scholar
Shmagel KV, Chereshnev VA (2009) Molecular bases of immune complex pathology. Biochem Mosc 74:469–479
CAS
Google Scholar
Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S (2006) Novel approaches in the treatment of systemic mastocytosis. Cancer 107:1429–1439
CAS
PubMed
Google Scholar
Rogers AS, Israel E, Smith CR, Levine D, McBean AM, Valente C, Faich G (1988) Physician knowledge, attitudes, and behavior related to reporting adverse drug events. Arch Intern Med 148:1596–1600
CAS
PubMed
Google Scholar
Ruppert AM, Averous G, Stanciu D, Deroide N, Riehm S, Poindron V, Pauli G, Debry C, de Blay F (2008) Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol 121:253–254
CAS
PubMed
Google Scholar
Scott HD, Rosenbaum SE, Waters WJ, Colt AM, Andrews LG, Juergens JP, Faich GA (1987) Rhode Island physicians’ recognition and reporting of adverse drug reactions. R I Med J 70:311–316
CAS
PubMed
Google Scholar
Slapnicar C, Trinkaus M, Hicks L, Vadas P (2019) Efficacy of Omalizumab in indolent systemic mastocytosis. Case Rep Hematol 3787586
Starke P (2015) Clinical review of Xolair (omalizumab) - FDA; BLA STN 103976/5149; https://www.fda.gov› media › download
Stokes J (2017) Anti-IgE treatment for disorders other than asthma. Front Med (Lausanne) 4:152
Google Scholar
Theoharides TC, Valent P, Akin C (2015) Mast cells, mastocytosis, and related disorders. N Engl J Med 373:163–172
CAS
PubMed
Google Scholar
Thomson NC, Chaudhuri R (2012) Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med 6:27–40
CAS
PubMed
PubMed Central
Google Scholar
Tridente G (2014) Adverse effects with biomedicines: prevention through understanding. Springer, Germany
Valent P, Akin C, Sperr WR, Mayerhofer M, Födinger M, Fritsche-Polanz R, Sotlar K, Escribano L, Arock M, Horny HP, Metcalfe DD (2005) Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 46:35–48
CAS
PubMed
Google Scholar
Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, Castells M, Escribano L, Hartmann K, Lieberman P, Nedoszytko B, Orfao A, Schwartz LB, Sotlar K, Sperr WR, Triggiani M, Valenta R, Horny HP, Metcalfe DD (2012) Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 157:215–225
PubMed
Google Scholar
Vichyanond P (2011) Omalizumab in allergic diseases, a recent review. Asian Pac J Allergy Immunol 29:209–219
CAS
PubMed
Google Scholar
Weiss SL, Smith DM (2019) A case of serum sickness-like reaction in an adult treated with Omalizumab. Mil Med doi. https://doi.org/10.1093/milmed/usz357
Zampetti A (2018) Mastocytosis- a new therapeutic scenario with omalizumab. Int J Aller Medications 4:027
Google Scholar
Zen M, Canova M, Campana C, Bettio S, Nalotto L, Rampudda M, Ramonda R, Iaccarino L, Doria A (2011) The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 10:305–310
CAS
PubMed
Google Scholar